NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Esperovax

Esperovax

Private
Plymouth, MichiganHealthcare & Life Scienceshttps://esperovax.com/

Last Round

Grant

Dec 12, 2024

Total Funding Raised

$3.41M

Company Overview

Esperovax is a biotechnology company that has developed a novel mRNA oral vaccine platform to enable large-scale production and distribution of shelf-stable vaccines.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Defense Tech, Clinical Trials

Business Model

B2G

Customer Profile

Government Contracts, Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

oral mRNA vaccinesoral biologics platformyeast-based deliverythermostable vaccinesvaccine pillmRNA delivery platformoral vaccinebiodefenseshelf-stable vaccinesmucosal immunitybiothreat countermeasuresRNA pillcold-chain freeplatform licensingpreclinical development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Esperovax Comparables

Compare Esperovax with similar companies based on industry and business-model similarity.

Esperovax comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Fzata, Inc.
82%
iosBio
79%
GIVAX
75%

Esperovax Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 12, 2024
GrantAug 23, 2023
SeedApr 29, 2021
Convertible DebtApr 9, 2021
Convertible DebtJan 19, 2021
Grant
Sep 23, 2020

Esperovax Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 24, 2026

    Monthly visitors grew 80% MoM, from 670 to 1.2K.

  • May 1, 2025

    Monthly visitors increased 907% to 1.4K.

Esperovax Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Esperovax Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Esperovax's valuation, stock price, and market status.

Firmographic Details

HeadquartersPlymouth, Michigan
Employee Range5
Year Founded2018
Last FundingDec 12, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.